Japan Lifeline Co., Ltd., a prominent medical device company, has announced a corporate reorganization set to take effect on July 1, 2025. The company's Board of Directors resolved to abolish the Global OEM Initiative Office within the R&D and Production Group, along with the Production Control and Procurement Departments of the Supply Chain Division. Despite these changes, the functions of the Production Control and Procurement Departments will continue to be managed by the Supply Chain Division. This restructuring aims to streamline operations and enhance efficiency.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.